AngioScore receives FDA marketing clearance for PTA Scoring Balloon Catheter
October 28, 2017
???We are very pleased to have received this important 510(k) clearance,??? said Thomas R. Trotter, President and CEO of AngioScore. ???Sales of AngioSculpt devices for the treatment of Peripheral Artery Disease (PAD) have been growing rapidly, and the opportunity to now include renal arteries is a major positive development for the company. PAD is one of the fastest-growing segments of the Endovascular Market, with over two million annual procedures worldwide, including an estimated 300,000 renal interventions.???
The AngioSculpt Scoring Balloon Catheter represents the next generation in angioplasty catheters. Its innovative nitinol scoring element provides unique anti-slipping properties while circumferentially dilating plaque, providing a precise and predictable dilatation across a wide range of lesion types. The AngioSculpt provides the versatility and effectiveness of a new technology together with the simplicity and deliverability of a high-performance balloon catheter.
Source AngioScore